<DOC>
	<DOCNO>NCT01195766</DOCNO>
	<brief_summary>The aim study analyze efficacy O-ESHAP treatment Hodgkin 's lymphome patient first line chemotherapy treatment failure due refractoriness , partial response relapse . In way , mortality , global survival free-progression survival O-ESHAP treatment TAPH also analyze .</brief_summary>
	<brief_title>Study Ofatumumab ESHAP Treatment Hodgkin 's Lymphoma</brief_title>
	<detailed_description>In addition : - To asses complete response rate O-ESHAP . - To asses toxicity O-ESHAP regimen - To asses stem cell mobilization capacity O-ESHAP regimen - To evaluate final result whole procedure ( O-ESHAP follow high-dose chemotherapy ASCT ) : transplant-related mortality ( TRM ) , overall survival ( OS ) , progression free survival ( PFS ) - To investigate correlation overall response CD20 expression tumoral cell .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients histologically confirm relapse , partial response refractory classical HL first line chemotherapy . They include irrespective CD20 expression HRS cell . CD20 expression analyze available biopsy data record evaluation . Age 18 65 year . Patient &gt; 65 &lt; 70 year old ECOG &lt; 2 absence comorbidities include study consider adequate investigator . Leucocytes &gt; 3,0 x 109/L platelet &gt; 100 x 109/L . ECOG &lt; 2 . No major organ dysfunction . Written informed consent . HIV negative . No active hepatitis B C infection . Availability histological report biopsy diagnosis relapse availability biopsy revise reference pathologist . Absence neoplasia , except basocellular tumor carcinoma uterine cervix situ . Contraception measure fertile female . Subjects current active hepatic biliary disease presence pathology would contraindicate administration chemotherapy HIV positive Hepatitis B C infection history malignancy addition specify inclusion criterion inform consent sign Pregnant / breastfeed reproductive capacity adult use effective method birth control study treatment least six month later . An effective method use least one barrier mechanism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hodgkin</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Lymphoma</keyword>
</DOC>